KEYNOTE-146: Lenvatinib Plus Pembrolizumab as Early-Line Treatment of Advanced Endometrial Cancer

May 29-31, 2020; Online at
Lenvatinib plus pembrolizumab showed promising efficacy as early-line treatment for patients with advanced endometrial cancer that is not MSI-H or dMMR in this post hoc analysis of KEYNOTE-146.
Format: Microsoft PowerPoint (.ppt)
File Size: 208 KB
Released: June 5, 2020


Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by educational grants from
Merck Sharp & Dohme Corp
Novartis Pharmaceuticals Corporation

Related Content

In this commentary from Clinical Care Options (CCO), Alexander Drilon, MD, discusses best practices in the use of TRK inhibitor therapy

person default Alexander Drilon, MD Released: July 10, 2020

Antitumor activity of lurbinectedin plus irinotecan in SCLC, endometrial carcinoma, and soft tissue sarcoma from ASCO 2020, as reported by Clinical care Options (CCO)

Released: June 4, 2020

Expert commentary on the recent expanded indication for niraparib from Clinical Care Options (CCO)

person default Kathleen Moore, MD Released: November 26, 2019

Multidisciplinary expert panel consisting of a physician, a nurse, and a pharmacist discuss optimal use of PARP inhibitors in ovarian cancer from various perspectives.

Laura Alwan Headshot Laura Alwan, PharmD, BCOP person default Virginia Bayer, BSN, RN, OCN Robert L. Coleman, MD Physicians: maximum of 1.75 AMA PRA Category 1 Credits Registered Nurses: 1.7 Nursing contact hours Pharmacists: 1.75 contact hours (0.175 CEUs) Released: September 25, 2019 Expired: September 24, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?